<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583905</url>
  </required_header>
  <id_info>
    <org_study_id>170HT/DL17007</org_study_id>
    <nct_id>NCT03583905</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-330 and D086 Combination Therapy in Hypertensive Patients With Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Evaluate the Efficacy and Safety of CKD-333
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety
      of CKD-330 and D086 Combination Therapy in Hypertensive Patients with Dyslipidemia
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2018</start_date>
  <completion_date type="Actual">July 17, 2019</completion_date>
  <primary_completion_date type="Actual">July 17, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change rate from baseline in LDL-C</measure>
    <time_frame>8 weeks after drug administrations</time_frame>
    <description>Compare experimental group 1 with placebo group 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in MSSBP</measure>
    <time_frame>8 weeks after drug administrations</time_frame>
    <description>Compare experimental group 1 with placebo group 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change rate from baseline in LDL-C</measure>
    <time_frame>4 weeks after drug administrations</time_frame>
    <description>Compare experimental group 1 with placebo group 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in LDL-C</measure>
    <time_frame>4, 8 weeks after drug administrations</time_frame>
    <description>Compare experimental group 1 with placebo group 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attainment of LDL-C treatment goal as defined by NCEP ATP Ⅲ Guideline</measure>
    <time_frame>4, 8 weeks after drug administrations</time_frame>
    <description>Compare experimental group 1 with placebo group 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in MSSBP(mmHg)</measure>
    <time_frame>4 weeks after drug administrations</time_frame>
    <description>Compare experimental group 1 with placebo group 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in MSDBP</measure>
    <time_frame>4, 8 weeks after drug administrations</time_frame>
    <description>Compare experimental group 1 with placebo group 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attainment of normal blood pressure as defined by JNC Ⅶ</measure>
    <time_frame>4, 8 weeks after drug administrations</time_frame>
    <description>Compare experimental group 1 with placebo group 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TC</measure>
    <time_frame>4, 8 weeks after drug administrations</time_frame>
    <description>Compare experimental group 1 with placebo group 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TG</measure>
    <time_frame>4, 8 weeks after drug administrations</time_frame>
    <description>Compare experimental group 1 with placebo group 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HDL-C</measure>
    <time_frame>4, 8 weeks after drug administrations</time_frame>
    <description>Compare experimental group 1 with placebo group 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change rate from baseline in TC</measure>
    <time_frame>4, 8 weeks after drug administrations</time_frame>
    <description>Compare experimental group 1 with placebo group 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change rate from baseline in TG</measure>
    <time_frame>4, 8 weeks after drug administrations</time_frame>
    <description>Compare experimental group 1 with placebo group 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change rate from baseline in HDL-C</measure>
    <time_frame>4, 8 weeks after drug administrations</time_frame>
    <description>Compare experimental group 1 with placebo group 1</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Hypertensive Patients With Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Experimental Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to this group are treated with CKD-330, D086</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the D086)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the CKD-330)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-330</intervention_name>
    <description>CKD-330 Tab.</description>
    <arm_group_label>Experimental Group 1</arm_group_label>
    <arm_group_label>Placebo Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of CKD-330</intervention_name>
    <description>Placebo of CKD-330 Tab.</description>
    <arm_group_label>Placebo Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D086</intervention_name>
    <description>D086 Tab.</description>
    <arm_group_label>Experimental Group 1</arm_group_label>
    <arm_group_label>Placebo Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of D086</intervention_name>
    <description>Placebo of D086 Tab.</description>
    <arm_group_label>Placebo Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D723</intervention_name>
    <description>D723 Tab.</description>
    <arm_group_label>Placebo Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of D723</intervention_name>
    <description>Placebo of D723 Tab.</description>
    <arm_group_label>Experimental Group 1</arm_group_label>
    <arm_group_label>Placebo Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a mean sitting systolic blood pressure (MSSBP) ≥ 140 mmHg measured on
             selected arms after run-in period

          2. Lipid levels measured after run-in period were:

               -  Group 1: hypertension + dyslipidemia only → fasting LDL-C ≥ 160 mg / dL

               -  Group 2: hypertension + dyslipidemia + cardiovascular risk factor more than 1 →
                  fasting LDL-C ≥ 130mg / dL

               -  Group 3: hypertension + dyslipidemia + coronary artery disease or equivalent or
                  10-year risk assessed by Framingham Point Score greater than 20% → fasting LDL-C
                  ≥ 100 mg / dL

        Exclusion Criteria:

          1. Patients whose blood pressures measured at Visit 2 were:

               -  Patients with MSSBP ≥ 180 mmHg and / or MSDBP ≥ 110 mmHg

          2. Patients who had lipid levels measured at Visit 2

               -  Patients with fasting LDL-C &lt;100 mg / dL or fasting LDL-C&gt; 250 mg / dL and / or
                  TG ≥ 500 mg / dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyunghee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Medical Center Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Medical Center Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

